CryoPort Inc (NASDAQ:CYRX) has been assigned an average broker rating score of 1.25 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. CryoPort’s rating score has improved by 6% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Analysts have set a 12 month consensus price target of $11.00 for the company and are predicting that the company will post ($0.07) earnings per share for the current quarter, according to Zacks. Zacks has also assigned CryoPort an industry rank of 166 out of 265 based on the ratings given to related companies.
Several analysts have recently commented on CYRX shares. Roth Capital started coverage on shares of CryoPort in a research report on Thursday, November 30th. They issued a “buy” rating and a $12.50 price target on the stock. Janney Montgomery Scott raised their target price on shares of CryoPort from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, October 3rd.
CryoPort (NASDAQ:CYRX) opened at $8.36 on Friday. The company has a market capitalization of $214.54, a PE ratio of -16.39 and a beta of 0.99. CryoPort has a 52 week low of $1.96 and a 52 week high of $10.40.
CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Wednesday, November 1st. The consumer goods maker reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). CryoPort had a negative net margin of 91.28% and a negative return on equity of 46.99%. equities research analysts predict that CryoPort will post -0.32 earnings per share for the current fiscal year.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.